Pharma BD Deal Intelligence

Transgene / ProBioGen

2026 · Licensing/Option · Complete

Transgene S.A. (Euronext Paris: TNG) and ProBioGen expanded their existing strategic partnership with an additional license agreement giving Transgene rights to the ProBioGen AGE1.CR.pIX suspension cell line. AGE1.CR.pIX is a stable proliferating avian cell line derived from primary duck embryo cells, developed as an alternative to chicken eggs for large-scale vaccine production and optimized for viral vaccine yield, scalability and genetic stability in chemically defined, animal-component-free medium. The license is intended to enhance manufacturing capabilities for the Transgene individualized cancer vaccine program and its myvac platform at clinical and commercial scale. Financial terms and the specific products covered were not disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Oncology deals